Press Contact

PPTA staff is available to assist the news media on a daily basis.

Mat Gulick
mgulick@pptaglobal.org
Director, Global Communications
Office: +1.443.458.4669
Fax: +1.410.263.2298

For questions about the National Donor Deferral Registry, call 443-433-1102.

Media and Information

PPTA News

EU Health Commissioner says plasma donation plays a vital role +

June 14, 2021 (Brussels, Belgium) – The Plasma Protein Therapeutics Association (PPTA) is proud to mark World Blood Donor Day. This day is an opportunity to specifically thank plasma donors, as well as blood donors, and recognize their shared commitment and contributions to saving and improving the lives of patients in Europe.
Read More
Study Shows Immunoglobulin Therapy is “Critical and Cost-Effective” in Treating CVID +

The journal publication, “Immunoglobulin Replacement Therapy is critical and cost-effective in increasing life expectancy and quality of life in patients suffering from Common Variable Immunodeficiency Disorders (CVID): A health-economic assessment,” is authored by Professor Philippe van Wilder with the Université libre de Bruxelles and Professor Esther de Vries of Tilburg University and offers a health economic model to estimate the value of treatment with IG therapy for CVID patients.
Read More
New position statement by CHMP regarding donor deferral criteria for sexual behaviour helps assessment of PMFs +

The International Plasma and Fractionation Association and the Plasma Protein Therapeutics Association are pleased with the recent publication by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) "CHMP Position statement on quality and safety assessment for the Plasma Master File (PMF) certification with regard to donor deferral criteria for sexual risk behaviour," as such a position was highly needed, especially regarding men-having-sex-with-men (MSM). It clarifies that the application of these nationally defined deferral periods will from now on also be considered when assessing appropriateness of locally collected plasma to be included in a PMF.
Read More
Lifting of long-time ban on use of UK plasma for manufacturing of immunoglobulins will help patients +

February 25, 2021 (Annapolis, MD) - The Plasma Protein Therapeutics Association (PPTA) welcomes the decision of the UK government to lift a two decades old ban on the use of UK-donated plasma for the manufacture of immunoglobulins, following a scientific review conducted by the Medicines and Healthcare Products Regulatory Agency. The ban was imposed in 1998 to mitigate the spread of variant Creutzfeldt Jakob Disease (vCJD), but experts have now concluded that the use of UK-sourced plasma to manufacture immunoglobulins is safe and can recommence, supported by a set of robust safety measures.
Read More

› ‹

The Source, the international magazine of the plasma protein therapeutics industry, is published quarterly.

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.

"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.

Get involved and follow "How Is Your Day?" on social media @HIYDglobal

Press Contact

PPTA staff is available to assist the news media on a daily basis.

Media and Information

Advocacy